Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.47 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 7/20 | 0.44 |
| ▸ | GRIN2D known ✓ | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B known ✓ | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 known ✓ | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B known ✓ | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C known ✓ | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1184796 | 0.98 | SIRT1 (0.51) | SIRT1ITGB3ITGA2BTRPV1SIGMAR1 | |
| SCHEMBL18980991 | 0.90 | SIRT1 (0.48) | SIRT1ITGB3ITGA2BTRPV1SIGMAR1 | |
| Nitric Acid SCHEMBL7265166 | 0.88 | SIRT1 (0.47) | SIRT1ITGB3ITGA2BTRPV1SIGMAR1 | |
| Nitric Acid SCHEMBL1185253 | 0.88 | SIRT1 (0.47) | SIRT1ITGB3ITGA2BTRPV1SIGMAR1 | |
| [3-(Hydroxymethyl)Phenyl]Guanidine SCHEMBL1186272 | 0.84 | PRSS1 (0.55) | ITGB3ITGA2BTRPV1SIGMAR1GRIN2D | |
| SCHEMBL19000835 | 0.83 | SIGMAR1 (0.62) | ITGB3ITGA2BSIGMAR1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL6680642 | 0.83 | LOXL2 (0.53) | ITGB3ITGA2BSIGMAR1GRIN2DGRIN3B | |
| SCHEMBL5960303 | 0.81 | KMT2A (0.56) | SIRT1ITGB3ITGA2BTRPV1SIGMAR1 | |
| SCHEMBL7873185 | 0.81 | TRPV1 (0.46) | SIRT1ITGB3ITGA2BTRPV1SIGMAR1 | |
| SCHEMBL28347492 | 0.81 | ITGB3 (0.43) | ITGB3ITGA2BSIGMAR1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189036-B1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS | ARQULE INC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-111494378-A | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-107074769-B | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2020-04-07 | — | — | CN | disclosed |
| US-9949981-B2 | Compositions and methods for treating proliferation disorders | ARQULE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| CN-107074769-A | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-3189036-A1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS | ArQule, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20160067260-A1 | Compositions and Methods for Treating Proliferation Disorders | ARQULE, INC. | 2016-03-10 | — | — | US | disclosed |
| WO-2016037044-A1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS | ARQULE, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| EP-2379506-B1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE INC (US) | 2015-09-02 | — | — | EP | disclosed |
| CN-102325755-B | Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds | ARQULE INC | 2015-07-01 | — | — | CN | disclosed |
| US-8357694-B2 | Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds | ARQULE, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8349827-B2 | Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds | ARQULE, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2414360-A1 | SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2379506-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ArQule, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010114898-A1 | SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249108-A1 | SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100239525-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010078421-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F] ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067260-A1 | Compositions and Methods for Treating Proliferation Disorders | MKI67, HRAS, VHL | ITGB3 3458/4885ITGA2B 4283/4885SIGMAR1 3615/4885 |
| US-20100249108-A1 | SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS | PDXK, DPYD, DHFR | ITGB3 4195/4885ITGA2B 4674/4885SIGMAR1 2994/4885 |
| US-20100239525-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | NQO1, DPYD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ITGB3 3466/4885ITGA2B 3248/4885SIGMAR1 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.